Arca
Skip to content
Tools
Tools

MAPK1: Mitogen-activated protein kinase 1

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on MAPK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved0

    Phase 30

      Phase 22

      • Ulixertinib
      • Ravoxertinib

      Phase 11

      • MK-8353

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: MAP kinase ERK2 inhibitor.
      UlixertinibPhase 2BioMed Valley Discoveries, IncSmall moleculeInhibitor9
      RavoxertinibPhase 2RocheSmall moleculeInhibitor0
      MK-8353Phase 1Merck & Co. (MSD)Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisUlixertinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer CenterJan 14, 2025
      Ulixertinib in People With Histiocytic NeoplasmsUlixertinibPhase 2RecruitingMemorial Sloan Kettering Cancer CenterMay 13, 2024
      Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)UlixertinibPhase 2Active, not recruitingNational Cancer Institute (NCI)May 6, 2024
      Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyUlixertinibPhase 1RecruitingM.D. Anderson Cancer CenterAug 14, 2023
      Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated GliomasUlixertinibEarly phase 1RecruitingM.D. Anderson Cancer CenterApr 7, 2023
      Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)UlixertinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Oct 9, 2018
      Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsUlixertinibPhase 1RecruitingUNC Lineberger Comprehensive Cancer CenterMar 5, 2018
      Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)UlixertinibPhase 2Active, not recruitingNational Cancer Institute (NCI)May 16, 2017

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Noonan syndrome 130.67
      • Noonan syndrome0.67
      • Cancer0.63
      • Atypical behavior0.51
      • Abnormal facial shape0.51
      • Specific learning disability0.51
      • Cervical squamous cell carcinoma0.51
      • Intellectual disability0.51
      • Costello syndrome0.51
      • Congenital heart disease0.49
      • Short stature0.48

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4040, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P28482, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.